Morganti et al. compared clinicopathological characteristics and clinical outcomes between a cohort of 51 patients with primary ER+/HER2− and paired triple-negative metastasis and two control cohorts of paired early-metastatic ER+/HER2− and triple-negative breast cancers and observed intermediate clinicopathological features and outcomes compared with tumors without receptor conversion at metastatic relapse [37]. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.